Company Overview
GRI Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of therapies designed to target diseases associated with inflammatory, fibrotic, and autoimmune disorders within the United States market. This operational focus places the company firmly within the Healthcare sector, specifically the Biotechnology industry, where capital-intensive research and development activities are standard for firms seeking to bring novel treatments to patients. The company's current scale is defined by a market capitalization of $3.29M and a workforce consisting of only three employees, reflecting the early-stage nature of its operations. These valuation and staffing metrics indicate that GRI Bio is a micro-cap entity with minimal operational footprint, suggesting that its primary value proposition relies on the potential future success of its pipeline rather than existing commercial revenue streams or established market share.
Financial Health
The financial statements for GRI Bio, Inc. report a Net Income (TTM) of $-11,956,000 and an EBITDA of $-11,973,000, while Revenue (TTM) is listed as N/A. The substantial gap between the reported revenue status and the significant net loss reveals a cost structure dominated by high research and development expenses typical of clinical-stage biotechnology firms that have not yet generated commercial sales. The company reports Free Cash Flow of $-5,468,625, which indicates a continued burn rate that consumes cash reserves while the company attempts to advance its product candidates through clinical trials. Margins across the board are zero, with Gross Margin at 0.0%, Operating Margin at 0.0%, and Profit Margin at 0.0%, indicating that the company has not yet achieved profitability or generated sufficient revenue to cover its operating costs. On the balance sheet, the company holds $8.23M in cash against a debt load of $71,000, resulting in a Debt to Equity ratio of 1.18, which presents an interesting leverage dynamic for a firm with no operating cash flow. The Current Ratio stands at 3.25, suggesting that the company possesses a conservative liquidity position with current assets significantly exceeding current liabilities. However, the Return on Equity is -238.2% and the Return on Assets is -103.9%, metrics that reveal management has not yet generated positive returns on the capital invested in the company.
Valuation Assessment
Valuation multiples for GRI Bio, Inc. present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings and a Forward P/E of -0.28. The negative forward P/E implies that the market is pricing in expectations of continued negative earnings growth or a turnaround in profitability that has not yet materialized. The Price to Book ratio is 0.19, indicating that the market values the company at less than one-fifth of its book value, which suggests the market places little premium on its intangible assets and future potential relative to its accounting equity. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of 0.41, which reflects a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization that is heavily influenced by the company's negative earnings position. The stock has exhibited extreme volatility over the past year, trading between a 52-Week High of $311.36 and a 52-Week Low of $2.10. Given the 52-week range, the current market price sits significantly below the historical high, reflecting a sharp correction from its peak valuation. The Beta is -1.20, a unique metric for this sector that indicates the stock price moves inversely to the broader market with high sensitivity, contributing to its wide trading range.
Growth & Income
Growth metrics for the company show Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, reflecting the lack of a commercial revenue base to measure year-over-year expansion. Without established revenue streams, the comparison between earnings and revenue growth rates is not applicable, as the company is still in the phase of converting research into commercial products. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute any portion of its earnings to shareholders. This 0.0% payout ratio is consistent with its status as a growth-stage biotechnology firm that retains all available capital to fund its clinical trials and operational expenses rather than paying dividends. The overall growth and income profile is characterized by a complete absence of current income generation and measured growth, relying entirely on the successful advancement of its lead product candidate, GRI-0621, to transition into a revenue-generating phase in the future.